Biogen's Q1 Earnings Call to Focus on BIIB080 Data and Apellis Deal, Oppenheimer Says

MT Newswires Live04-22

Biogen's (BIIB) Q1 earnings call will likely focus on data from the BIIB080 Alzheimer's disease study expected mid-year, Oppenheimer analysts said in a note emailed Wednesday.

The company is scheduled to report its Q1 financial results on April 29.

Oppenheimer analysts expect the company to post Q1 adjusted earnings of $2.96 a share. Analysts polled by FactSet expect $2.99.

Oppenheimer said that BIIB080's phase 2 results are Biogen's largest near-term catalyst, as competitors' topline misses underscore high barriers to entry in the anti-tau field.

Analysts said that another key focus in the earnings call will be the implications of Biogen's deal to acquire Apellis Pharmaceuticals (APLS).

Oppenheimer has an outperform rating on the stock and a $275 price target.

Price: 190.50, Change: +4.55, Percent Change: +2.44

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629025691?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 23:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629025691","market":"us","top_or_hot":-1,"title":"Biogen's Q1 Earnings Call to Focus on BIIB080 Data and Apellis Deal, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> Biogen's (BIIB) Q1 earnings call will likely focus on data from the BIIB080 Alzheimer's disease study expected mid-year, Oppenheimer analysts said in a note emailed Wednesday.</p><p>The company is scheduled to report its Q1 financial results on April 29.</p><p>Oppenheimer analysts expect the company to post Q1 adjusted earnings of $2.96 a share. Analysts polled by FactSet expect $2.99.</p><p>Oppenheimer said that BIIB080's phase 2 results are Biogen's largest near-term catalyst, as competitors' topline misses underscore high barriers to entry in the anti-tau field.</p><p>Analysts said that another key focus in the earnings call will be the implications of Biogen's deal to acquire Apellis Pharmaceuticals (APLS).</p><p>Oppenheimer has an outperform rating on the stock and a $275 price target.</p><p>Price: 190.50, Change: +4.55, Percent Change: +2.44</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen's Q1 Earnings Call to Focus on BIIB080 Data and Apellis Deal, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen's Q1 Earnings Call to Focus on BIIB080 Data and Apellis Deal, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-22 23:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biogen's (BIIB) Q1 earnings call will likely focus on data from the BIIB080 Alzheimer's disease study expected mid-year, Oppenheimer analysts said in a note emailed Wednesday.</p><p>The company is scheduled to report its Q1 financial results on April 29.</p><p>Oppenheimer analysts expect the company to post Q1 adjusted earnings of $2.96 a share. Analysts polled by FactSet expect $2.99.</p><p>Oppenheimer said that BIIB080's phase 2 results are Biogen's largest near-term catalyst, as competitors' topline misses underscore high barriers to entry in the anti-tau field.</p><p>Analysts said that another key focus in the earnings call will be the implications of Biogen's deal to acquire Apellis Pharmaceuticals (APLS).</p><p>Oppenheimer has an outperform rating on the stock and a $275 price target.</p><p>Price: 190.50, Change: +4.55, Percent Change: +2.44</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2629025691","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629025691","pubTimestamp":1776872920,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biogen's  Q1 earnings call will likely focus on data from the BIIB080 Alzheimer's disease study expected mid-year, Oppenheimer analysts said in a note emailed Wednesday.The company is scheduled to report its Q1 financial results on April 29.Oppenheimer analysts expect the company to post Q1 adjusted earnings of $2.96 a share. Analysts polled by FactSet expect $2.99.Oppenheimer said that BIIB080's phase 2 results are Biogen's largest near-term catalyst, as competitors' topline misses underscore high barriers to entry in the anti-tau field.Analysts said that another key focus in the earnings call will be the implications of Biogen's deal to acquire Apellis Pharmaceuticals .Oppenheimer has an outperform rating on the stock and a $275 price target.Price: 190.50, Change: +4.55, Percent Change: +2.44","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司","OPY":"奥本海默控股"},"translate_title":"Oppenheimer表示，Biogen第一季度盈利看涨期权将重点关注BIIB080数据和Apellis交易","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5,"OPY":1.5},"content_text":"Biogen's (BIIB) Q1 earnings call will likely focus on data from the BIIB080 Alzheimer's disease study expected mid-year, Oppenheimer analysts said in a note emailed Wednesday.The company is scheduled to report its Q1 financial results on April 29.Oppenheimer analysts expect the company to post Q1 adjusted earnings of $2.96 a share. Analysts polled by FactSet expect $2.99.Oppenheimer said that BIIB080's phase 2 results are Biogen's largest near-term catalyst, as competitors' topline misses underscore high barriers to entry in the anti-tau field.Analysts said that another key focus in the earnings call will be the implications of Biogen's deal to acquire Apellis Pharmaceuticals (APLS).Oppenheimer has an outperform rating on the stock and a $275 price target.Price: 190.50, Change: +4.55, Percent Change: +2.44","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629025691","isCrawlerRequest":true}